HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine

Abstract : Introduction Urgent action is needed to fight the ongoing coronavirus disease 2019 (COVID-19) pandemic by reducing the number of infected cases, contagiousness and severity. Chlorpromazine (CPZ), an antipsychotic from the phenothiazine group, is known to inhibit clathrin-mediated endocytosis and has antiviral activity against severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus. The aim of this in-vitro study was to test CPZ against SARS-CoV-2 in monkey and human cells. Materials and methods Monkey VeroE6 cells and human alveolar basal epithelial A549-ACE2 cells were infected with SARS-CoV-2 in the presence of various concentrations of CPZ. Supernatants were harvested at day 2 and analysed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) for the presence of SARS-CoV-2 RNA. Cell viability was assessed in non-infected cells. Results CPZ was found to have antiviral activity against SARS-CoV-2 in monkey VeroE6 cells, with a half maximal inhibitory concentration (IC50) of 8.2 µM, half maximal cytotoxic concentration (CC50) of 13.5 µM, and selectivity index (SI) of 1.65. In human A549-ACE2 cells, CPZ was also found to have anti-SARS-CoV-2 activity, with IC50 of 11.3 µM, CC50 of 23.1 µM and SI of 2.04. Discussion Although the measured SI values are low, the IC50 values measured in vitro may translate to CPZ dosages used in routine clinical practice because of the high biodistribution of CPZ in lungs and saliva. Also, the distribution of CPZ in brain could be of interest for treating or preventing neurological and psychiatric forms of COVID-19. Conclusions These preclinical findings support clinical investigation of the repurposing of CPZ, a drug with mild side effects, in the treatment of patients with COVID-19.
Document type :
Journal articles
Complete list of metadata

Contributor : Hélène Ribierre Connect in order to contact the contributor
Submitted on : Friday, July 2, 2021 - 4:33:15 PM
Last modification on : Thursday, April 7, 2022 - 1:58:20 PM

Links full text



Marion Plaze, David Attali, Matthieu Prot, Anne-Cécile Petit, Michael Blatzer, et al.. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. International Journal of Antimicrobial Agents, Elsevier, 2021, 57 (3), pp.106274. ⟨10.1016/j.ijantimicag.2020.106274⟩. ⟨pasteur-03277133⟩



Record views